What is NDC 23155-193?

23155-193 is the product NDC for Colistimethate Sodium, Colistimethate sodium 150 mg/4mL injection, powder, lyophilized, for solution, listed with the FDA by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., NDC labeler code 23155. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Colistimethate Sodium?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Colistimethate Sodium NDC 23155-193

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-193Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0193Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
23155-193-31	2315501933123155019331	1 VIAL, GLASS in 1 CARTON (23155-193-31) / 4 mL in 1 VIAL, GLASSMarketed from Sep 9, 2021
23155-193-41	2315501934123155019341	12 VIAL, GLASS in 1 CARTON (23155-193-41) / 4 mL in 1 VIAL, GLASSMarketed from Sep 9, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Colistimethate Sodium
Generic name (nonproprietary): colistimethate sodium
Active ingredients: Colistimethate sodium — 150 mg/4mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intramuscular, Intravenous
Labeler: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.NDC labeler code 23155
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202359
Marketing start: Sep 9, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Polymyxins (Chemical structure)
Identifiers: Product ID 23155-193_698b0d4f-1182-475f-aafb-bfcbd0b637f2SPL ID 698b0d4f-1182-475f-aafb-bfcbd0b637f2SPL set ID 6a335659-03b0-4a2d-9cd4-7dcf7da96fe6RxCUI 1117522UNII XW0E5YS77GUPC 0323155193312
Pharmacologic class: Polymyxin-class Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N423155019331 followed by a unit qualifier and the quantity

Package 23155-0193-31. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 4, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gr…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 23155-193

What is NDC 23155-193?: 23155-193 is the product NDC for Colistimethate Sodium, Colistimethate sodium 150 mg/4mL injection, powder, lyophilized, for solution, listed with the FDA by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Colistimethate Sodium.
What is the active ingredient?: Colistimethate sodium.
Who is the labeler?: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., NDC labeler code 23155. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Colistimethate Sodium?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.